BioNTech finds itself in an unusual bind. The Mainz-based biotech is sitting on roughly €16.8 billion in cash and marketable securities, yet its shares are trading near multi-month lows. A new $1 billion buyback launched on May 7 was supposed to send a vote of confidence. Instead, the stock has continued to slide. The equity […]
The post